AbbVie

Carbon per million dollars of revenue. The legacy industry-standard reference (CDP, MSCI). Useful for cross-sector context, but distorted by margin — high-margin firms appear artificially efficient. Read alongside the operational and asset intensities for the full picture.

OpEx (operating expenditure) is the running cost of the business — staff, services, energy, materials. This shows how carbon-intensive operations are per million dollars of spend. Removes the margin distortion that revenue-based ratios introduce.

EVIC (Enterprise Value Including Cash) is the firm's total capital footprint — equity + debt + cash + minority interest. The EU's standard intensity measure (SFDR PAI 3) — answers: how much carbon does each million of capital deployed in this business produce?

PP&E (Property, Plant & Equipment) plus leased real-estate assets is the firm's physical infrastructure on the balance sheet. This shows the carbon intensity of that physical footprint — uses Scope 1+2+3 for consistency with the other headline intensities. Surfaces stranded-asset risk for asset-heavy firms.

AbbVie has a centralized Renewable Energy fund to increase active sourcing of renewable electricity. Progress reached 83.2% by year-end 2025 (up from 29.5% in 2021 baseline), with target of 100% by 2030. AbbVie procures renewable electricity through Energy Attribute Certificates including RECs, IRECs and European Guarantees of Origin. On-site photovoltaic solar installations operate at six sites: Ballytivnan (Ireland), Barceloneta (Puerto Rico), Campoverde (Italy), Ludwigshafen (Germany), Heredia (Costa Rica), and Liège (Belgium). Campoverde solar plant expansion delivered ~900 tCO2e annual savings.

AbbVie has not purchased, and does not currently anticipate purchasing, carbon offset credits to meet its near-term science-based targets. Decarbonization relies on direct operational reductions, fleet electrification, energy efficiency, renewable electricity procurement, and supplier engagement rather than removals or offsets.

• Energy efficiency at manufacturing/R&D sites

  Centralized capital expenditure fund supports energy-efficiency and GHG-reduction projects. In 2025, $15.1 million was allocated to approximately 65 projects (solar upgrades, boilers, chillers, insulation, heat recovery, air compressors, VSDs, LED lighting, HVAC), expected to cut ~3,700 tCO2e. Achieved 8% Scope 1+2 reduction since 2021; targeting 5–7% additional reduction by 2030.

• Fleet electrification and hybridization

  Project Green Wave promotes business prioritization and employee selection of electric, hybrid and biofuel vehicles. By end of 2025, AbbVie had more than 4,800 electric and hybrid vehicles globally (up from ~1,300 in 2021). Achieved 1.5% Scope 1 reduction; targeting 7–10% Scope 1 reduction by 2030.

• Physical footprint optimization

  Ongoing assessment of global affiliate real estate footprint and optimization of manufacturing capabilities and sites. Achieved 21.5% Scope 1+2 reduction since 2021; targeting 10–15% reduction by 2030. AbbVie is integrating resiliency, energy efficiency and decarbonization into design and construction of new facilities, including a $100 billion US R&D and capex commitment over the next decade.

• Green chemistry and lab-process efficiency

  AbbVie follows the Twelve Principles of Green Chemistry and uses pervaporation (membrane-based solvent reduction) and thin film evaporation at North Chicago API Pilot Plant to reduce solvent use, energy and waste. Multiple R&D sites earned My Green Lab certifications in 2025 (e.g., Pringy, France: Green Level).

• Supplier engagement on Scope 3 (SBTi cascade)

  Engagement focuses on encouraging suppliers in Purchased Goods & Services, Capital Goods, and Upstream Transportation & Distribution categories to set their own SBTi-aligned targets. By end of 2025, 51.4% of suppliers (by emissions in these categories) had set science-based GHG reduction targets, up from 15.7% in 2021 baseline; 2027 target is 79.1%.

• Sustainable packaging and product carbon footprints

  Launched PCF Roadmap in 2025 using PAS 2090:2025 framework, with pilots in select markets and plans to expand across portfolio over three years. New SYNTHROID bottle cut plastic >23%; new MAVYRET blister cut plastic >280g/pack and paper 120g/pack; SkinMedica primary packaging 90% recyclable.